SG11202002581WA - Anti-gd2 antibody for the treatment of neuroblastoma - Google Patents
Anti-gd2 antibody for the treatment of neuroblastomaInfo
- Publication number
- SG11202002581WA SG11202002581WA SG11202002581WA SG11202002581WA SG11202002581WA SG 11202002581W A SG11202002581W A SG 11202002581WA SG 11202002581W A SG11202002581W A SG 11202002581WA SG 11202002581W A SG11202002581W A SG 11202002581WA SG 11202002581W A SG11202002581W A SG 11202002581WA
- Authority
- SG
- Singapore
- Prior art keywords
- neuroblastoma
- antibody
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192476 | 2017-09-21 | ||
| PCT/NL2018/050629 WO2019059771A2 (en) | 2017-09-21 | 2018-09-21 | ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002581WA true SG11202002581WA (en) | 2020-04-29 |
Family
ID=59955406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002581WA SG11202002581WA (en) | 2017-09-21 | 2018-09-21 | Anti-gd2 antibody for the treatment of neuroblastoma |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11866511B2 (https=) |
| EP (1) | EP3684818A2 (https=) |
| JP (2) | JP2020534370A (https=) |
| KR (1) | KR20200059249A (https=) |
| CN (1) | CN111278862A (https=) |
| AU (3) | AU2018336017B2 (https=) |
| BR (1) | BR112020005742A2 (https=) |
| CA (1) | CA3076482A1 (https=) |
| IL (1) | IL273454A (https=) |
| MX (1) | MX2020003201A (https=) |
| SG (1) | SG11202002581WA (https=) |
| WO (1) | WO2019059771A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114096559B (zh) * | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| CN111849904B (zh) * | 2020-07-31 | 2021-05-04 | 浙江科途医学科技有限公司 | 神经母细胞瘤类器官的培养基、培养方法及移植体 |
| EP4326292A4 (en) * | 2021-04-23 | 2025-03-26 | Vivasor, Inc. | Dimeric antigen receptors (dars) that bind gd2 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4724490A2 (en) | 2023-06-12 | 2026-04-15 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284536B1 (en) | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| EP1916257A1 (en) * | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| US8313730B2 (en) | 2006-12-13 | 2012-11-20 | Michael R. Simon | Treatment of celiac disease with IgA |
| EP2578681B1 (en) | 2010-05-24 | 2015-07-01 | Kagoshima University | Iga-binding peptide and iga purification using same |
| EP2465536A1 (en) | 2010-12-14 | 2012-06-20 | CSL Behring AG | CD89 activation in therapy |
| EP2791170A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
| BR112014022240A2 (pt) | 2012-03-09 | 2017-08-01 | Csl Behring Ag | composições compreendendo imunoglobulinas semelhantes à secretoras |
| WO2013189516A1 (en) * | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| US9890216B2 (en) | 2012-10-23 | 2018-02-13 | Board Of Regents, The University Of Texas System | Antibodies with engineered IgG Fc domains |
| CN106414494B (zh) * | 2013-11-12 | 2020-09-18 | Ogd2药物 | 具有促凋亡活性的人IgG1衍生的抗体 |
| ES2768649T3 (es) * | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
| CN105732814B (zh) * | 2016-03-08 | 2019-05-28 | 苏州大学 | 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用 |
| EP3747438A1 (en) | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
-
2018
- 2018-09-21 EP EP18812321.0A patent/EP3684818A2/en active Pending
- 2018-09-21 JP JP2020538517A patent/JP2020534370A/ja active Pending
- 2018-09-21 CA CA3076482A patent/CA3076482A1/en active Pending
- 2018-09-21 AU AU2018336017A patent/AU2018336017B2/en active Active
- 2018-09-21 WO PCT/NL2018/050629 patent/WO2019059771A2/en not_active Ceased
- 2018-09-21 KR KR1020207011096A patent/KR20200059249A/ko not_active Ceased
- 2018-09-21 MX MX2020003201A patent/MX2020003201A/es unknown
- 2018-09-21 BR BR112020005742-8A patent/BR112020005742A2/pt not_active IP Right Cessation
- 2018-09-21 CN CN201880065543.8A patent/CN111278862A/zh active Pending
- 2018-09-21 SG SG11202002581WA patent/SG11202002581WA/en unknown
-
2020
- 2020-03-19 IL IL273454A patent/IL273454A/en unknown
- 2020-03-20 US US16/825,563 patent/US11866511B2/en active Active
- 2020-12-23 US US17/132,989 patent/US20210179732A1/en active Pending
-
2021
- 2021-09-23 AU AU2021236513A patent/AU2021236513A1/en not_active Abandoned
-
2023
- 2023-11-06 JP JP2023189702A patent/JP2024023238A/ja active Pending
-
2025
- 2025-02-26 AU AU2025201363A patent/AU2025201363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018336017B2 (en) | 2021-06-24 |
| US20210179732A1 (en) | 2021-06-17 |
| KR20200059249A (ko) | 2020-05-28 |
| BR112020005742A2 (pt) | 2020-10-13 |
| US20200283541A1 (en) | 2020-09-10 |
| CN111278862A (zh) | 2020-06-12 |
| JP2020534370A (ja) | 2020-11-26 |
| AU2025201363A1 (en) | 2025-03-20 |
| EP3684818A2 (en) | 2020-07-29 |
| MX2020003201A (es) | 2020-08-13 |
| AU2021236513A1 (en) | 2021-10-21 |
| CA3076482A1 (en) | 2019-03-28 |
| JP2024023238A (ja) | 2024-02-21 |
| WO2019059771A3 (en) | 2019-10-10 |
| US11866511B2 (en) | 2024-01-09 |
| NZ762835A (en) | 2024-12-20 |
| IL273454A (en) | 2020-05-31 |
| WO2019059771A2 (en) | 2019-03-28 |
| AU2018336017A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273454A (en) | An antibody against ganglioside GD2 for the treatment of neuroblastoma | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| IL275482A (en) | Asketamine for the treatment of depression | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| HUE063044T2 (hu) | Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| HUE055263T2 (hu) | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére | |
| ZA201807509B (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| EP3227276A4 (en) | Combinations for the treatment of neuroblastoma | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL268835B (en) | A process for the preparation of 2-cyanoimidazole compounds | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| PL3448340T3 (pl) | Pomocniczy element aplikacyjny do opatrywania ran | |
| HUE063118T2 (hu) | Eljárás N-alkil-nitrátoetilnitraminok elõállítására | |
| IL271236A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| IL265268A (en) | Combinations including 196 abx for sabertan treatment | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| ZA202004466B (en) | Processes for the synthesis of sulfentrazone | |
| IL275480A (en) | A process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
| ZA201901948B (en) | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections | |
| PT3759082T (pt) | Processo para a síntese de 6-clorometiluracilo | |
| PT3713939T (pt) | Processo melhorado para a síntese de fármaco ligante vcseco- duba | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin |